Print ERC_15_4_cover

Society for Endocrinology

Endocrine -Related Cancer

• Cellular and Molecular Biology of Hormones and Growth Factors Pathogenetic in Cancer

• Hormone-Dependent Neoplasms• Hormonal Carcinogenesis

DECEMBER 2008Volume 15Issue 4ISSN 1351-0088 (print)ISSN 1479-6821 (online)

Endocrinology on the web:www.endocrinology.org

Endocrine-Related CancerVolum

e 15Num

ber 4Decem

ber 2008Pages 841–1133

1351-0088(200812)15:4;1-T

ERC 15_4_cover.qxp 11/11/08 3:36 PM Page 1

Announcements

Joint Symposium Obesity and Metabolic Diseases Special

Interest Group and Clinical Pharmacology Section 17

December 2008, Brighton, UK. Contact: Sarah Mackay,

British Pharmacological Society (Email: [email protected])

Fertility 2009 7–9 January 2009, Edinburgh, UK. Contact:

Jessica Canfor, Profile Productions Ltd, Northumberland

House, 11 The Pavement, Popes Lane, London, W5 4NG,

UK (Tel: 020 8832 7311; Fax: 020 8832 7301; Email:

[email protected]; Web:

http://www.fertility2009.org/)

Type 2 Diabetes and Insulin Resistance 20–25 January

2009, Banff, Canada. Contact: Keystone symposia

(Email: [email protected];

Web: http://www.keystonesymposia.org/

Meetings/ViewMeetings.cfm?MeetingID=996)

Obesity: Novel Aspects of the Regulation of Body Weight

20–25 January 2009, Banff, Canada. Contact: Keystone

symposia (Email: [email protected]; Web:

http://www.keystonesymposia.org/


Expanding Boundaries of Endocrinology 27 January 2009,

London, UK. Contact: Jo Summers, Royal College of

Physicians, London, UK (Email:


http://www.rcplondon.ac.uk/event/details.aspx?e=1379)

Ion Channels as Therapeutic Targets 2009 5–6 February

2009, Novartis Horsham Research Centre, Horsham, UK.

Contact: BPS (Email: [email protected]; Web:

http://www.bps.ac.uk)

Course in Advanced Endocrinology 6–8 February 2009,

Grand Copthorne Waterfront Hotel, Singapore. Contact:

Sarah Ten (Email: [email protected]; Web:

http://www.endometab.com/index.shtml)

5th Asia-Oceana Conference on Obesity 6–8 February 2009,

Mumbai, India. Contact: Mr Euan Woodward, Obesity

International Trading Ltd, 231 North Gower Street, London,

NW1 2NR, UK (Tel: +44 (0) 20 7691 1900; Email:


http://aiaaro.com/aiaaro2009/)

Society for Endocrinology Clinical Cases Meeting in

association with the RSM 10 February 2009, London,

UK. Contact: Conference team (Email: conferences

@endocrinology.org; Web:

http://www.endocrinology.org/meetings/2009/cc2009/)

Complications of Diabetes and Obesity 24 February–1

March 2009, Vancouver, Canada. Contact: Keystone

symposia (Email: [email protected]; Web:

http://www.keystonesymposia.org/


52nd Symposium of the German Endocrine Society DGE

4–7 March 2009, Giessen, Germany. Contact: Reinhard G

Bretzel, Third Medical Department, University Hospotal

Giessen and Marburg, Rodthohl 6, D-35392, 35392,

Germany (Tel: +49 (0) 641 994 2750; Fax: +49 (0) 641 994

2759; Email: [email protected];

Web: http://www.giessen2009.de)

6th Annual ENETS Conference 5–7 March 2009, Granada,

Spain. Contact: ENETS (Email: [email protected];

Web: http://www.neuroendocrine.net/rel/)

ISCD 15th Annual Meeting 11–14 March 2009, Orlando, USA.

Contact: International Society for Clinical Densitometry

(Tel: 860 586 7563; Fax: 860 586 7550; Email:

[email protected]; Web: http://www.iscd.org/)

Diabetes UK Annual Professional Conference 2009 11–13

March 2009, Glasgow, Scotland. Contact: Conferences

Team, Macleod House, 10 Parkway, London, NW1 7AA,

UK (Tel: 0207 424 1000; Fax: 0207 424 1081; Email:


http://www.diabetes.org.uk/apc2009)

Society for Endocrinology BES 2009 16–19 March 2009,

Harrogate, UK. Contact: Shirine Borbor, Society for

Endocrinology, 22 Apex Court, Woodlands, Bradley Stoke,

Bristol, BS32 4JT, UK (Tel: +44 (0)1454 642 210; Fax: +44

(0)1454 642 222; Email: [email protected];

Web: http://www.endocrinology.org/meetings/2009/

sfebes2009/)

ECCEO 9 Athens 2009 18–21 March 2009, Athens, Greece.

Contact: YP Communication, Boulevard G. Kleyer, 108,

B-4000 Liege, Belgium (Tel: +32 (0)4 254 12 25; Fax: +32

(0)4 254 12 90; Email: [email protected]

com; Web: http://www.ecceo9.org/index.html)

2nd Joint Meeting of the International Bone and Mineral

Society and the Australian & New Zealand Bone &

Mineral Society 21–25 March 2009, Sydney, Australia.

Contact: International Bone and Mineral Society (Web:

http://www.ibms2009.com/)

Cell Death Pathways 22–27 March 2009, Whistler, Canada.

Contact: Keystone Symposia (Email: info@keystone-

symposia.org; Web: http://www.keystonesymposia.

org/Meetings/ViewMeetings.cfm?MeetingID=970)

European Association for the Study of Obesity Bjorntorp

Symposium 24–27 March 2009, Prague, Czech Republic.

Contact: EASO, 231 North Gower Street, London, NW1

2NR, UK (Email: [email protected]; Web:

http://www.easo.org/)

3rd International Meeting on Skeletal Endocrinology 27

March 2009, University of Brescia, Italy. Contact:

Secretariat (Email: [email protected]; Web:

http://www.skeletal-endocrinology.org/presentazione.asp)

Announcements

43rd Annual European Society for Clinical Investigation,

Frankfurt 1–4 April 2009, Frankfurt / Main, Germany.

Contact: Nicola Bock-Schildbach, Congress & Promotion,

Amselweg 7, Konigstein 61462, Germany (Tel: +49 (0)

6174/933595; Fax: +49 (0) 6174/933596; Email: Bock-


http://www.esci2009.com)

IASO Stock Conference: Obesity and Inflammation 3–6

April 2009, Cairns, Australia. Contact: IASO (Tel: +44 (0)

207 691 1900; Email: [email protected]; Web:

http://www.iaso.org/stock2009.asp)

ASBMB 2009 Annual Meeting 18–22 April 2009, New

Orleans, USA. Contact: ASBMB, ASBMB Meetings Office,

9650 Rockville Pike, Bethesda, MD, USA, 20814-3996

(Email: [email protected]; Web:

http://www.asbmb.org/Page.aspx?id=146)

British Neuroscience Association 20th National Meeting -

Liverpool 2009 19–22 April 2009, Liverpool, UK. Contact:

British Neuroscience Association (Email: bna2009@liv.

ac.uk; Web: http://www.bna.org.uk/bna2009/)

3rd Focused Meeting Cell Signalling 20–21 April 2009, The

University of Leicester, Leicester, UK. Contact: BPS

(Email: [email protected]; Web: http://www.bps.ac.uk)

11th European Congress of Endocrinology 25–29 April

2009, Istanbul, Turkey. Contact: European Society of

Endocrinology, c/o Sezen Elagoz, TeamCon Congress

Services Worldwide, Halaskargazi Caddesi Alp Palas Apt.

No:79/1, 34371 Harbiye, Istanbul, (Tel: +90 212 343 80 03;

Fax: +90 212 343 80 23; Email: [email protected];

Web: http://www.ece2009.com/)

American Association of Endocrine Surgeons Annual

Meeting 2009 2–5 May 2009, Madison, USA. Contact:

AAES (Email: [email protected]; Web:

http://www.endocrinesurgery.org/mtgs/

future_meetings.cfm)

17th European Congress on Obesity - ECO 2009 6–9 May

2009, Amsterdam, Netherlands. Contact: ECO 2009

(Email: [email protected]; Web:

http://www.easoobesity.org/eco2009/)

American Association of Clinical Endocrinologists 18th

Annual Meeting and Clinical Congress 13–17 May

2009, Houston, USA. Contact: AACE, 245 Riverside Ave,

Suite 200, Jacksonville, Florida, 32202, USA

(Tel: 904-353-7878; Email: [email protected]; Web:

https://www.aace.com/meetings/

calendar/calendar.php)

3rd IVI International Congress 14–16 May 2009, Madrid,

Spain. Contact: comtecMED (Email: Info@Comtecmed.

com; Web: http://www.comtecmed.com/ivi/2009/

Default.aspx)

8th European Congress on Menopause 16–20 May 2009,

London, UK. Contact: Kenes International, 1-3 rue de

Chantepoulet, CH-1211 Geneva, Switzerland (Email:

[email protected]; Web: http://www.kenes.com/emas-

congress/)

36th European Symposium on Calcified Tissues 23–27 May

2009, Vienna, Austria. Contact: Amanda Sherwood, PO

Box 337, Patchway, Bristol, BS32 4ZR, UK (Tel: +44 (0)

1454 610255; Fax: +44 (0) 1454 610255; Email:

[email protected]; Web: http://www.ectsoc.org)

Announcements

Author guidelines for Endocrine-Related CancerThe scope of the journal

All types of basic, clinical and experimental investigationandobservation concerningendocrine-related cancers inhuman and animal subjects.

Types of papers

Reviews (and original research papers of exceptionalquality) are considered.

Submission of papers

Please submit online using the Manuscript Centralsystem. Guidelines for this can be found atwww.endocrinology.org/sfe/onlsub.htm. If you areunable to submit online please send yourmanuscript anda disk containing all files to the Editor-in-Chief,Endocrine-Related Cancer, 22 Apex Court, Woodlands,Bradley Stoke, Bristol BS32 4JT, UK.Tel: C44-(0)1454-42220; Fax: C44-(0)1454-642222.There is no charge for submitting papers nor will there beany subsequent page charges.

General instructions

If submitting by post, three copies of the manuscript,three sets of halftonefiguresandadisk containingall filesare required. Only one set of line drawings needs to be ofpublishable quality; the others may be photocopies.

When submitting a paper for consideration, authorsmust give written assurance that the work has not been,and will not be, submitted for publication elsewhere untilthe journal has reached a decision on whether to publishthe paper. If rejected the authors are free to submitelsewhere; if accepted the assurance automaticallyextends indefinitely. It will be assumed that submittedmanuscripts carry the approval of all the authors. Authorsare required to acknowledge all of the major sources offunding relevant to the research reported in theAcknowledgements section and to declare that there iseither: (a) no conflict of interest that would prejudice itsimpartiality; or (b) a potential conflict of interest that is fullydeclared within the text of the article.

Manuscripts must be in English and spelling shouldfollowTheShorterOxfordEnglishDictionaryorMerriam–Webster’s Collegiate Dictionary. All abbreviations mustbe defined. Manuscripts should be printed double-spaced, preferably in a Times font, and with a size of atleast 10 point.

To expedite refereeing the author should provideduplicate copies of papers quoted as ‘In Press’,particularly those concerned with methodology.

To facilitate the rapid processing of their paper authorsshould also provide a fax number and an email address.

Use of computer disks

If your paper is accepted for publication, or you are askedto revise, a word processor file for your paper and highresolution figures (see Figures section below) will berequested (the PDF files used for online peer review arenot suitable for typesetting).

Please provide files no larger than 15 MB via email [email protected], or onPC (DOS)-formatted disksif possible (this option is also available on manyMacintosh systems). The preferred word processingformat is RTF, but files produced using other packagescan be translated. Please provide printed copies of allfiles when supplying electronic versions.The disk/email should carry the text, references, figure

legends and tables. Diagrams and photographs shouldbe supplied as separate paper copies (andelectronic filesif possible).

Reviews

Title page

This should contain the complete title (please limit this toa maximum of 20 words), names of all authors, fulladdresses of all institutions (the address of the laboratorywhere the work was carried out should be given first) anda short title for page headings.

Abstract

The abstract (which should be no more than 5% of thelength of the paper) should summarize the main findingsof the paper and the conclusions reached.

References

In the text, references should be cited by giving the nameof the first author et al. where there are more than twoauthors. In the reference list all authors should be givenand the titles of the papers and the journals should bewritten in full. Examples of reference style are as follows:

See RH, Calvo D, Shi Y, Kawa H, Luke MP & Yuan Z2001 Stimulation of p300-mediated transcription by thekinase MEKK1. Journal of Biological Chemistry 27616310–16317.

Harvey SS 1975 Hypnotics and sedatives. Thebarbiturates. In Pharmacological Basis of Therapeutics,edn 5, pp 102–123. Eds LS Goodman & A Gilman. NewYork: Macmillan Publishing Co.

Endocrine-Related Cancer reference style for End Note(version 3 and above) is available from the online authorguidelines.

Please note that papers with incorrectly

formatted references will be returned and the

acceptancedate changed to thedateof receipt of

the correctly formatted paper.

Tables

Tables should have full and informative headings andshould be supplied electronically and as hard copy onseparate pages. Table columns should be set up usingsimple tabs rather than specialised table layouts.

Figures

General information

Three-dimensional graphs to show two-dimensional datashould be avoided and photo- and electronmicrographs

Author guidelines

www.endocrinology-journals.org

should contain scale bars. The cost of colourreproduction over and above that for black andwhitewill be charged to authors. This must be paid by creditcard before publication. Please see colour charges format www.endocrinology.org/sfe/colourack.pdf. Pleaseavoid grey or dotted backgrounds in all figures, as thesedo not reproduce well. Legends should enable the readerto understand the information contained in figureswithout reference to the text.

Paper copies

These should be provided even when electronic copiesare also supplied and should be numbered on separatepages, bearing the first author’s name. One set of linedrawings should be good quality originals, e.g. from alaser printer (not photocopies). There is no need tophotograph originals of line drawings.

Electronic copies (accepted papers only)

Once the article has been accepted we require thefollowing (as the 1 MB PDF file used for refereeing wouldbe unsuitable for printing):

† The text of the paper to besubmitted as separateRTFfile.

† The tables should be submitted in word format as aseparate file.

† For figures the formats required areB The line figures (graphs, bar diagrams) should also

be submitted as separatedEPS (resolution greaterthan 300 dpi) or TIFFS (resolution greter than1000 dpi).

B Scanned images or images from digital capturedevices (gels, confocal microscopy figures) shouldbe submitted as TIFF file (resolution greater than300 dpi): colour images should be saved in CMYKformat and mono images should be saved ingreyscale format.

You can find details of how to create high resolutionPDFsand illustrations in PowerPoint www.endocrinology-journals.org/misc/artwork.

Use of statistical analysis

To enable the reader to judge the validity of results, thenumber of experimental subjects used (n), and the extentof independent experimental repetition from which dataare taken, should be stated. Authors should, wherepossible, support their conclusions with appropriatestatistical analysis. The test used must be describedconcisely and the results presented clearly. The term‘significant’ should not be used without supportingevidence from statistical analysis and theP value used todetermine significance must be stated.

Original research papers

Themain emphasis of the journal is on review articles butoriginal articles may be accepted if of exceptional quality.The article should conform with the requirements forreviews and the text should generally follow the format:

Abstract, Introduction, Materials and methods, Results,Discussion and References.

Commentaries

The editor reserves the right to invite commentaries orcritiques on articles accepted for publication.

Ethics of experimental procedures onhuman subjects

Manuscripts must contain a statement that consent hasbeen obtained from each patient or subject after fullexplanation of the purpose and nature of all proceduresused. It must be stated that the investigation wasapproved by the local ethical committee, functioningaccording to the 3rd edition of the Guidelines on thePractice of Ethical Committees in Medical Researchissued by the Royal College of Physicians of London(11 St Andrew’s Place, London NW1 4LE, UK;Tel:C44 (0) 207 935 1174; FaxC44 (0) 207 7486 4514;Email: [email protected];Web: www.rcplondon.ac.uk). Copies of the MRCrecommendations can be obtained from the MedicalResearch Council, 20 Park Crescent, London W1B 1AL,UK (Tel: C44 (0) 20 7636 5422;Fax: C44 (0) 20 7636 6179) or via www.mrc.ac.uk.

Use of living animals

All papers describing experiments on animals shouldconform with The UFAW Handbook on the Care andManagement of Laboratory Animals, 7th edition,published by the Universities Federation for AnimalWelfare, The Old School, Brewhouse Hill,Wheathampstead, Herts AL4 8AN, UK(Tel: C44 (0) 1582 831818; Fax: C44 (0) 1582 831414;Web: http://www.ufaw.org.uk/pubs.htm#lab). Paperswhich do not conform with these guidelines or with UKlegal requirements cannot be accepted.

Copyright

Articles are considered on the understanding that, if theyare accepted for publication, the entire copyright shallpass to the Society for Endocrinology. All authors areasked to sign a copyright agreement to this effect. Tofacilitate the processing of your manuscript pleasecomplete the form printed on the following page andsubmit it with your paper. Requests for permission toreproduce any part of papers published in Endocrine-Related Cancer should be addressed to the PermissionsSecretary ([email protected]).

Self-archiving:institutional and other onlinerepositories

You may archive your final accepted article onto onlinerepositories, subject to various conditions set out in theSociety’s policy (www.endocrinology-journals.org/misc/archiving_policy.dtl).

Offprints

A free PDF will be emailed to the corresponding author.Offprints can be ordered on the form accompanying theproof.

Author guidelines


Endocrine-Related Cancer

This established journal offers a global forum for all types of basic, clinical and experimental investigation

and observation concerning endocrine-related cancer in human and animal subjects.

Subscribe to Endocrine-Related Cancer

Contains important review articles – All papers peer-reviewed – Reports conference and symposium

proceedings – Global coverage and editorial board

ISSN 1351-0088 (print) ISSN 1479-6821 (online) (Quarterly) Editor: Dr J A Fagin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Order formPlease enter my 2009 subscription to Endocrine-Related Cancer at

, The personal price of C= 350 (Europe)/$440 (N&S America)/£233 (UK & Rest of the World)

, The printConline institutional price of C= 1255 (Europe)/$1595 (N&S America)/£850 (UK & Rest of the World)

, The online only institutional price of C= 1205 (Europe)/$1520 (N&S America)/£815 (UK & Rest of the World)

, ERCCJOECJME: The printConline institutional price of C= 2725 (Europe)/$3530 (N&S America)/£1820

(UK & Rest of the World)

, Send me a proforma invoice

, Charge my Visa/Access/Mastercard (Number) Expiry date

Name

Address

Signature Date

If paying by credit card, please ensure you include your address where your credit card bills are sent, if different from above.

Please return this form to Society of Endocrinology, c/o Portland Press, Commerce Way, Colchester, CO2 8HP

(Tel: C44-1206-796351; Fax: C44-1206-799331; Email: [email protected]).

Large globalreadership

How to submit your paperReview articles (and original research papers of

exceptional quality) are considered. To submit

online using the Manuscript Central system go to

www.endocrinology.org/sfe/onlsub.htm or send

five copies of your manuscript (including figures

and tables) to the Editor, Endocrine-Related

Cancer, 22 Apex Court, Woodlands, Bradley

Stoke, Bristol BS32 4JT, UK.

To ease our handling of your paper, please

supply copies of any article cited as ‘in press’.

Tables and illustrations should be numbered and on

separate pages. Please supply glossy originals of

any photographs, and include scale bars on

micrographs. Line figures should be supplied as

laser-printed output or equivalent; avoid grey or

dotted shading. References should be listed

alphabetically and should include the full article

and journal titles. They should be cited by name and

date in the text. American and British spelling are

equally acceptable. All articles should include

abstracts.

A Society of Endocrinology publication

† No page or reviewing charges

† Cited in Current Contents

† High impact factor: 5.193

† High circulation

www.try-erc.orgwith free access to Advanced Abstracts

and Accepted Preprints.HTML and PDF full text available at

subscribing institutions

Assignment of copyrightto the Society for Endocrinology

In order to publish your article we need your agreement in writing. Please take a moment to read the terms ofthis assignment, sign the form and return it to us as quickly as possible.

Journal: Endocrine-Related Cancer

Title of article .......................................................................................................................................................................................................................

...............................................................................................................................................................................................................................................

Name(s) of author(s).............................................................................................................................................................................................................

...............................................................................................................................................................................................................................................

...............................................................................................................................................................................................................................................

Name of copyright owner, if not author(s) ..........................................................................................................................................................................

Address of above copyright owner (if applicable) ..............................................................................................................................................................

...............................................................................................................................................................................................................................................

† By signing this form, you (the author(s) or other copyright owner, such as your employer) agree to transfer to us (the Society forEndocrinology, the publisher) the copyright in the above article, thus giving us the exclusive right to reproduce, distribute and broadcast theabove article (including the abstract) ourselves throughout the world in printed, electronic or anyother medium, and in turn to authorize others(including Reproduction Rights Organisations such as the Copyright Licensing Agency and the Copyright Clearance Center) to do the same.You agree that we may publish your article in the journal named above, and that we may sell or distribute it within the journal, on its own, orwith other related material.† You confirm that all of the named authors contributed substantially to the article, and agree to take public responsibility for the validity of itscontent. You also confirm that all major sources of funding have been acknowledged in the text of the article, and that there is either (a) noconflict of interest that would prejudice its impartiality, or (b) a potential conflict of interest that is fully declared within the text of the article.† You promise that the article is your original work, has not previously been published, and is not currently under consideration by anotherjournal. If it containsmaterial (such as a previously published illustration) which is someone else’s copyright, you promise that you have obtainedthe unrestricted permission of the copyright owner (please attach evidence of this) and that the material is clearly identified and acknowledgedwithin the text. You also promise that the article does not, to the best of your knowledge, contain anything which is libellous, illegal, or infringesanyone’s copyright or other rights.† We promise that we will respect your rights as the author(s). That is, we will make sure that your name(s) is/are always clearly associatedwith the article and, while you do allow us to make necessary editorial changes, we will not make any substantial alteration to your articlewithout consulting you. We will have your article reviewed by impartial referees, and will let you know the outcome as quickly as we can. If thearticle is accepted, we undertake to publish it as soon as we reasonably can. If it is rejected, this agreement is automatically cancelled and all therights come back to you.†We will do everything we reasonably can to maximize the visibility of the journal, and of your article within it. We will mount your article’sabstract on our web site within a few days of acceptance. On final publication, we will send you an Acrobat PDF file of your article in its finalpublished form. You are free to use it in all the ways described in the next paragraph. We will also send you an order form to enable you to buyoffprints.†You remain free to use your own article for the internal educational or research purposes of your own institution or company and to use it, inwhole or in part, as the basis for your own further research or spoken presentations, provided you neither sell it nor encourage others to infringeour copyright.†Youmay self archive or otherwise deposit your final accepted manuscript on freely available institutional or other online repositories (such asNIH’s PubMed Central), provided (i) the version deposited is the manuscript, as finally accepted by the relevant journal but prior to copy editingand page formatting; (ii) you ensure that it will not become publicly available until 12 months after publication in the journal; (iii) themanuscript made available in this way includes the Society’s standard disclaimer (see http://www.endocrinology-journals.org/misc/archiving_poliy.dtl)

Signature(s) of Author(s)......................................................................................................................... Date ..............................................

................................................................................................................................................................. Date ..............................................

................................................................................................................................................................. Date ..............................................

................................................................................................................................................................. Date ..............................................

Note: every named author must sign this form, or a copy of it

Signature of Copyright Owner, if different............................................................................................. Date ..............................................

Please return this form by post or fax to the Society for Endocrinology, 22 Apex Court, Woodlands, Bradley Stoke, Bristol

BS32 4JT, UK (Fax +44(0)1454 642222).

By submitting your article to this journal, you agree that we may store your details on its manuscript database. We may occasionally use these details to send you

information about services we think will interest you. We will never pass your details to any other organization. If you would prefer not to receive any mailings from

us, please write to us at the above address.


Author guidelines

Endocrine – Related

Cancer

Volume 15

ISSN 1351–0088 (print)ISSN 1479–6821 (online)

Editor-in-Chief

Associate Editors

Founding Editor

Editorial Board

J A FaginNew York, NY, USA

C L Clarke

Sydney, Australia

V H T James

London, UK

J Adamski

Munich, Germany

N Bundred

Manchester, UK

W E Farrell

Keele, UK

W W de Herder

Rotterdam, Netherlands

S Menard

Milan, Italy

R Nicholson

Cardiff, UK

F Pacini

Siena, Italy

D S Salomon

Bethesda, MD, USA

C Stratakis

Bethesda, MD, USA

M van de Vijver

Amsterdam, Netherlands

A B Grossman

London, UK

S L Asa

Toronto, Canada

C Coombes

London, UK

W L Gerald

New York, NY, USA

J T Isaacs

Baltimore, MD, USA

M Motta

Milan, Italy

N Normanno

Naples, Italy

M Ringel

Columbus, OH, USA

M Santoro

Naples, Italy

W Tilley

Adelaide, Australia

J Wimalsena

Knoxville, TN, USA

K Knudsen

Philadelphia, PA, USA

X Bertagna

Paris, France

Z Culig

Innsbruck, Austria

A Heaney

Los Angeles, CA, USA

E Liu

Singapore

E Musgrove

Darlinghurst,NSW,Australia

K Pacak

Bethesda, MD, USA

B Robinson

Sydney, Australia

J W Simons

Baltimore, MD, USA

R Vigneri

Catania, Italy

Endocrine-Related Cancer is published by the

Society for Endocrinology (Limited by Guarantee).

The agent for distribution is Portland Press, PO Box 32,

Commerce Way, Whitehall Industrial Estate,

Colchester CO2 8HP, UK.

Copyright q2008 by the Society for Endocrinology.

Typeset and printed in Europe by the Alden Group, Oxfordshire, UK

Printed on acid-free paper.

Endocrine – Related

Cancer

Volume contents

Number 1 $ March 2008

Modulation of proteomic profile in H295Radrenocortical cell line induced by mitotane

A Stigliano, L Cerquetti, M Borro,G Gentile, B Bucci, S Misiti,P Piergrossi, E Brunetti,M Simmaco & V Toscano

1–10

The emergence of DNA methylation as akey modulator of aberrant cell death inprostate cancer

T M Murphy, A S Perry& M Lawler

11–25

Aromatase inhibitors for breast cancer:different structures, same effects?

Riccardo Ponzone, Paola Mininanni,Elisa Cassina, Francesca Pastorino& Piero Sismondi

27–36

Bone metastases from differentiated thyroidcarcinoma

M M Muresan, P Olivier, J Leclere,F Sirveaux, L Brunaud, M Klein,R Zarnegar & G Weryha

37–49

Thyroid stem cells: lessons from normaldevelopment and thyroid cancer

Dolly Thomas, Susan Friedman &Reigh-Yi Lin

51–58

Transforming growth factor-b signallingand ubiquitinators in cancer

Eric Glasgow & Lopa Mishra 59–72

Menopausal symptoms and adjuvanttherapy-associated adverse events

P Hadji 73–90

Arachidonic acid modulates the crosstalkbetween prostate carcinoma and bonestromal cells

Adriano Angelucci,Stefania Garofalo, Silvia Speca,Antonella Bovadilla, Giovanni LucaGravina, Paola Muzi,Carlo Vicentini & Mauro Bologna

91–100

2008

Volume 15

ISSN 1351–0088 (print)ISSN 1479–6821 (online)

Fibroblast growth factor receptor 4 predictsfailure on tamoxifen therapy in patientswith recurrent breast cancer

Danielle Meijer, Anieta M Sieuwerts,Maxime P Look, Ton van Agthoven,John A Foekens &Lambert C J Dorssers

101–111

Intratumoral concentration of sex steroidsand expression of sex steroid-producingenzymes in ductal carcinoma in situ ofhuman breast

Rie Shibuya, Takashi Suzuki,Yasuhiro Miki, Kimako Yoshida,Takuya Moriya, Katsuhiko Ono,Jun-ichi Akahira, Takanori Ishida,Hisashi Hirakawa, Dean B Evans &Hironobu Sasano

113–124

ABCC11 expression is regulated byestrogen in MCF7 cells, correlated withestrogen receptor a expression inpostmenopausal breast tumors andoverexpressed in tamoxifen-resistant breastcancer cells

Mylene Honorat, Aurelia Mesnier,Julie Vendrell, Jerome Guitton,Ivan Bieche, Rosette Lidereau,Gary D Kruh, Charles Dumontet,Pascale Cohen & Lea Payen

125–138

Enhanced expression of aromatase inp53-inactivated mammary epithelial cells

Hoo Kyun Choi, Sang Hee Roh,Hyung Gyoon Kim, Eun Hee Han,Hye Gwang Jeong &Keon Wook Kang

139–147

A novel vaccine targeting gastrin-releasingpeptide: efficient inhibition of breast cancergrowth in vivo

Wu Guojun, Guo Wei,Ouyan Kedong, He Yi, Xie Yanfei,Chen Qingmei, Zhang Yankai,Wu Jie, Fan Hao, Li Taiming,Liu Jingjing & Cao Rongyue

149–159

Global gene expression profiles induced byphytoestrogens in human breast cancer cells

Ramiro Dip, Sarah Lenz,Jean-Philippe Antignac,Bruno Le Bizec, Hans Gmuender &Hanspeter Naegeli

161–173

Cytological Ki-67 in pancreatic endocrinetumours: an opportunity for pre-operativegrading

Cecilia Piani, Giulia M Franchi,Chiara Cappelletti, Marina Scavini,Luca Albarello, Alessandro Zerbi,Paolo Giorgio Arcidiacono,Emanuele Bosi & Marco F Manzoni

175–181

Association of the T1799A BRAF mutationwith tumor extrathyroidal invasion, higherperipheral platelet counts, andoverexpression of platelet-derived growthfactor-B in papillary thyroid cancer

Yangang Wang, Meiju Ji,Wei Wang, Zhimin Miao,Peng Hou, Xinyan Chen, Feng Xu,Guangwu Zhu, Xianlu Sun,Yujun Li, Steven Condouris,Dingxie Liu, Shengli Yan, JiePan &Mingzhao Xing

183–190

BRAF(V600E) mutation and the biology ofpapillary thyroid cancer

F Frasca, C Nucera, G Pellegriti,P Gangemi, M Attard, M Stella,M Loda, V Vella, C Giordano,F Trimarchi, E Mazzon,A Belfiore & R Vigneri

191–205

Familial non-medullary thyroid carcinoma(FNMTC): analysis of fPTC/PRN, NMTC1,MNG1 and TCO susceptibility loci andidentification of somatic BRAF and RASmutations

Branca M Cavaco, Pedro F Batista,Carmo Martins, Ana Banito,Francisco do Rosario,Edward Limbert,Luıs G Sobrinho & Valeriano Leite

207–215

Deregulation of anti-Mullerianhormone/BMP and transforming growthfactor-b pathways in Leydig cell lesionsdeveloped in male heterozygous multipleendocrine neoplasia type 1 mutant mice

Nader Hussein, JieLi Lu,Huguette Casse, Sandra Fontaniere,Anne-Marie Morera,Severine Mazaud Guittot,Alain Calender,Nathalie Di Clemente &Chang X Zhang

217–227

Somatostatin-producing neuroendocrinetumors of the duodenum and pancreas:incidence, types, biological behavior,association with inherited syndromes, andfunctional activity

Nele Garbrecht, Martin Anlauf,Anja Schmitt, Tobias Henopp,Bence Sipos, Andreas Raffel,Claus F Eisenberger,Wolfram T Knoefel,Marianne Pavel, Christian Fottner,Thomas J Musholt, Anja Rinke,Rudolf Arnold, Uta Berndt, UrsulaPlockinger, Bertram Wiedenmann,Holger Moch, Philipp U Heitz, PaulKomminoth, Aurel Perren &Gunter Kloppel

229–241

Defining molecular classifications andtargets in gastroenteropancreaticneuroendocrine tumors through DNAmicroarray analysis

Eva-Maria Duerr, Yusuke Mizukami,Aylwin Ng, Ramnik J Xavier,Hirotoshi Kikuchi,Vikram Deshpande,Andrew L Warshaw,Jonathan Glickman,Matthew H Kulke &Daniel C Chung

243–256

Antitumor activity of rapamycin andoctreotide as single agents or incombination in neuroendocrine tumors

Amy Moreno, Argun Akcakanat,Mark F Munsell, Alpana Soni,James C Yao &Funda Meric-Bernstam

257–266

Parathyroid tumor development involvesderegulation of homeobox genes

H-C Jennifer Shen,Jennifer E Rosen, Lauren M Yang,Sharon A Savage, A Lee Burns,Carmen M Mateo, Sunita K Agarwal,Settara C Chandrasekharappa,Allen M Spiegel, Francis S Collins,Stephen J Marx & Steven K Libutti

267–275

Anti-cancer actions of a recombinantantibody (R6313/G2) against theangiotensin II AT1 receptor

M A Redondo-Muller,M Stevanovic-Walker, S Barker,J R Puddefoot & G P Vinson

277–288

Adiponectin receptor expression is elevatedin colorectal carcinomas but not ingastrointestinal stromal tumors

Catherine J Williams,Nicholas Mitsiades,Elias Sozopoulos, Alex Hsi,Alicja Wolk, Artemissia-Phoebe Nifli,Sofia Tseleni-Balafouta &Christos S Mantzoros

289–299

Characterization of gastrin–cholecystokinin2 receptor interaction in relation to c-fosinduction

Martine J Hollestelle,Peter Timmerman, Rob H Meloen &Jo W M Hoppener

301–309

Role of positron emission tomography andbone scintigraphy in the evaluation of boneinvolvement in metastaticpheochromocytoma and paraganglioma:specific implications for succinatedehydrogenase enzyme subunit B genemutations

Tomas Zelinka,Henri J L M Timmers,Anna Kozupa, Clara C Chen,Jorge A Carrasquillo,James C Reynolds,Alexander Ling, Graeme Eisenhofer,Ivica Lazurova, Karen T Adams,Millie A Whatley, Jirı Widimsky Jr& Karel Pacak

311–323

The insulin receptor: a new anticancertarget for peroxisome proliferator-activatedreceptor-g (PPARg) and thiazolidinedione-PPARg agonists

V Costa, D Foti, F Paonessa,E Chiefari, L Palaia, G Brunetti,E Gulletta, A Fusco & A Brunetti

325–335

Gastric endocrine tumors type I: treatmentwith long-acting somatostatin analogs

D Campana, F Nori, R Pezzilli,L Piscitelli, D Santini, E Brocchi,R Corinaldesi & P Tomassetti

337–342

Over-expression of ERBB-2 was morefrequently detected in malignant thanbenign pheochromocytomas by multiplexligation-dependent probe amplification andimmunohistochemistry

WenQi Yuan, WeiQinq Wang,Bin Cui, TingWei Su, Yan Ge,Lei Jiang, WeiWei Zhou &Guang Ning

343–350

Roles of estrogen receptor a and b inmodulating urothelial cell proliferation

Jian Teng, Zun-Yi Wang,David F Jarrard & Dale E Bjorling

351–364


Erratum 365–366

Announcements

Author Guidelines

Number 2 $ June 2008

Signal transducer and activator oftranscription 5A/B in prostate and breastcancers

Shyh-Han Tan & Marja TNevalainen

367–390

Endocannabinoids in endocrine and relatedtumours

Maurizio Bifulco, Anna MariaMalfitano, Simona Pisanti &Chiara Laezza

391–408

Pancreatic endocrine neoplasms:epidemiology and prognosis of pancreaticendocrine tumors

Thorvardur R Halfdanarson,Joseph Rubin, Michael B Farnell,Clive S Grant & Gloria M Petersen

409–427

Analysis of single nucleotidepolymorphisms of FSH receptor genesuggests association with testicular cancersusceptibility

Alberto Ferlin, Manuel Pengo,Riccardo Selice, Luigi Salmaso,Andrea Garolla & Carlo Foresta

429–437

Patterns and changes in gene expressionfollowing neo-adjuvant anti-estrogentreatment in estrogen receptor-positivebreast cancer

Vera Cappelletti, Manuela Gariboldi,Loris De Cecco, Sara Toffanin,James F Reid, Lara Lusa, EmilioBajetta, Luigi Celio, Marco Greco,Alessandra Fabbri, Marco APierotti & Maria Grazia Daidone

439–449

Estrogen signaling ability in humanendometrial cancer through thecancer–stromal interaction

Mitsuyo Matsumoto, Yuri Yamaguchi,Yuko Seino, Atsushi Hatakeyama,Hiroyuki Takei, Hitoshi Niikura,Kiyoshi Ito, Takashi Suzuki,Hironobu Sasano, Nobuo Yaegashi& Shin-ichi Hayashi

451–463

Expression of progesterone and estradiolreceptors in normal adrenal cortex,adrenocortical tumors, and primarypigmented nodular adrenocorticaldisease

Patricia de Cremoux, Dan Rosenberg,Jacques Goussard, CatherineBremont-Weil, Frederique Tissier,Carine Tran-Perennou, LionnelGroussin, Xavier Bertagna, JeromeBertherat & Marie-LaureRaffin-Sanson

465–474


Estrogen promotes tumor progression in agenetically defined mouse model of lungadenocarcinoma

Zane Hammoud, Bailin Tan,Sunil Badve & Robert M Bigsby

475–483

Endogenous sex hormones and endometrialcancer risk in women in the EuropeanProspective Investigation into Cancer andNutrition (EPIC)

Naomi E Allen, Timothy J Key,Laure Dossus, Sabina Rinaldi,Anne Cust, Annekatrin Lukanova,Petra H Peeters, N CharlotteOnland-Moret, Petra H Lahmann,Franco Berrino, Salvatore Panico,Nerea Larranaga, Guillem Pera,Maria-Jose Tormo, Maria-JoseSanchez, J Ramon Quiros,Eva Ardanaz, Anne Tjønneland,Anja Olsen, Jenny Chang-Claude,Jakob Linseisen, Mandy Schulz,Heiner Boeing, Eva Lundin,Domenico Palli, Kim Overvad,Francoise Clavel-Chapelon,Marie-Christine Boutron-Ruault,Sheila Bingham, Kay-Tee Khaw,H Bas Bueno-de-Mesquita, AntoniaTrichopoulou, DimitirosTrichopoulos, Androniki Naska,Rosario Tumino, Elio Riboli &Rudolf Kaaks

485–497

Cytotoxic effects of a novelpyrazolopyrimidine derivative entrapped inliposomes in anaplastic thyroid cancer cellsin vitro and in xenograft tumors in vivo

M Celano, S Schenone, D Cosco,M Navarra, E Puxeddu,L Racanicchi, C Brullo, E Varano,S Alcaro, E Ferretti, G Botta,S Filetti, M Fresta, M Botta& D Russo

499–510

BRAFV600E mutation, but not RET/PTCrearrangements, is correlated with a lowerexpression of both thyroperoxidase andsodium iodide symporter genes in papillarythyroid cancer

Cristina Romei, Raffaele Ciampi,Pinuccia Faviana, Laura Agate,Eleonora Molinaro, Valeria Bottici,Fulvio Basolo, Paolo Miccoli,Furio Pacini, Aldo Pinchera &Rossella Elisei

511–520

Interactions between sphingosine-1-phosphate and vascular endothelial growthfactor signalling in ML-1 follicular thyroidcarcinoma cells

Sonja Balthasar, Nina Bergelin,Christoffer Lof, Minna Vainio,Sture Andersson & Kid Tornquist

521–534

Regulation of tumor necrosis factor-relatedapoptosis-inducing ligand-inducedapoptosis by DJ-1 in thyroid cancer cells

Hai-Yan Zhang, Hua-Qin Wang,Hai-Mei Liu, Yifu Guan &Zhen-Xian Du

535–544


Peroxisome proliferator-activated receptorg inhibits follicular and anaplastic thyroidcarcinoma cells growth by upregulatingp21Cip1/WAF1 gene in a Sp1-dependentmanner

D Bonofiglio, H Qi, S Gabriele,S Catalano, S Aquila, M Belmonte& S Ando

545–557

Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derivedcell lines

Yannick Arlot-Bonnemains,Enke Baldini, Benedicte Martin,Jean-Guy Delcros, Matteo Toller,Francesco Curcio, FrancescoS Ambesi-Impiombato, MassiminoD’Armiento & Salvatore Ulisse

559–568

Amyloid precursor-like protein 1 isdifferentially upregulated inneuroendocrine tumours of thegastrointestinal tract

Yvonne Arvidsson, Ellinor Andersson,Anders Bergstrom, Mattias KAndersson, Gulay Altiparmak,Ann-Christin Illerskog, Hakan Ahlman,Darima Lamazhapova & Ola Nilsson

569–581

Efficacy of a dopamine–somatostatinchimeric molecule, BIM-23A760, in thecontrol of cell growth from primary culturesof human non-functioning pituitaryadenomas: a multi-center study

Tullio Florio, Federica Barbieri,Renato Spaziante, Gianluigi Zona,Leo J Hofland, Peter M vanKoetsveld, Richard A Feelders,Gunter K Stalla, MarilyTheodoropoulou, Michael D Culler,Jesse Dong, John E Taylor, Jacques-Pierre Moreau, Alexandru Saveanu,Ginette Gunz, Henry Dufour &Philippe Jaquet

583–596

Predicting values of lipids and white bloodcell count for all-site cancer in type 2diabetes

Xilin Yang, Wing-Yee So, RonaldC W Ma, Gary T C Ko, AliceP S Kong, Qingsheng Wang, Clive SCockram, Chun-Chung Chow,Juliana C N Chan & Peter C Y Tong

597–607

Methylation of the p16INK4A promoter isassociated with malignant behavior inabdominal extra-adrenal paragangliomasbut not pheochromocytomas

N B Kiss, J Geli, F Lundberg, C Avci,D Velazquez-Fernandez, J Hashemi,G Weber, A Hoog, T J Ekstrom,M Backdahl & C Larsson

609–621

Mitotane increases the radiotherapyinhibitory effect and induces G2-arrest incombined treatment on both H295R andSW13 adrenocortical cell lines

L Cerquetti, B Bucci, R Marchese,S Misiti, U De Paula, R Miceli,A Muleti, D Amendola, P Piergrossi,E Brunetti, V Toscano & A Stigliano

623–634

Targeted therapy for adrenocortical tumorsin transgenic mice through their LHreceptor by Hecate-human chorionicgonadotropin b conjugate

Susanna Vuorenoja, AdolfoRivero-Muller, Adam J Ziecik,Ilpo Huhtaniemi, Jorma Toppari &Nafis A Rahman

635–648


Announcements

Author Guidelines

Number 3 $ September 2008

Endocrine disruptors and prostate cancerrisk

Gail S Prins 649–656

Integrins in prostate cancer progression Hira Lal Goel, Jing Li,Sophia Kogan & Lucia R Languino

657–664

Design and validation of specific inhibitorsof 17b-hydroxysteroid dehydrogenases fortherapeutic application in breast andprostate cancer, and in endometriosis

Joanna M Day, Helena J Tutill,Atul Purohit and Michael J Reed

665–692

Medical treatment as an alternative toadrenalectomy in patients with aldosterone-producing adenomas

Asterios Karagiannis, KonstantinosTziomalos, Anna I Kakafika,Vasilios G Athyros, Faidon Harsoulis& Dimitri P Mikhailidis

693–700

Somatostatin analogues in the control ofneuroendocrine tumours: efficacy andmechanisms

Simona Grozinsky-Glasberg,Ilan Shimon, Marta Korbonits &Ashley B Grossman

701–720

Pituitary tumor-transforming gene inendocrine and other neoplasms: a reviewand update

Fateme Salehi, Kalman Kovacs,Bernd W Scheithauer, Ricardo V Lloyd& Michael Cusimano

721–743

Cyclooxygenase-2 predicts adverse effectsof tamoxifen: a possible mechanism of rolefor nuclear HER2 in breast cancer patients

Mary F Dillon, Anthony T Stafford,Gabrielle Kelly, Aisling M Redmond,Marie McIlroy, Thomas B Crotty,E McDermott, Arnold D Hill &Leonie S Young

745–753

Low phosphorylation of estrogen receptor a(ERa) serine 118 and high phosphorylationof ERa serine 167 improve survival in ER-positive breast cancer

Hiroko Yamashita, Mariko Nishio,Tatsuya Toyama, Hiroshi Sugiura,Naoto Kondo, Shunzo Kobayashi,Yoshitaka Fujii & Hirotaka Iwase

755–763

Downregulation of Aurora-A overridesestrogen-mediated growth andchemoresistance in breast cancer cells

Heng Hong Lee, Yansong Zhu,Karthik M Govindasamy & GanesanGopalan

765–775


Evaluation of a functional epigeneticapproach to identify promoter regionmethylation in phaeochromocytoma andneuroblastoma

Caroline D E Margetts, Mark Morris,Dewi Astuti, Dean C Gentle,Alberto Cascon, Fiona E McRonald,Daniel Catchpoole, Mercedes Robledo,Hartmut P H Neumann, Farida Latif& Eamonn R Maher

777–786

Re-expression of ABI3-binding proteinsuppresses thyroid tumor growth bypromoting senescence and inhibitinginvasion

Flavia R M Latini,Jefferson P Hemerly, Gisele Oler,Gregory J Riggins & Janete M Cerutti

787–799

Array-CGH identifies cyclin D1 andUBCH10 amplicons in anaplastic thyroidcarcinoma

Jia-Jing Lee, Amy Y M Au,Theodoros Foukakis, Michela Barbaro,Nimrod Kiss, Roderick Clifton-Bligh,Johan Staaf, Ake Borg,Leigh Delbridge, Bruce G Robinson,Goran Wallin, Anders Hoog &Catharina Larsson

801–815

Oct-1 induces pituitary tumor transforminggene expression in endocrine tumors

Cuiqi Zhou, Yunguang Tong,Kolja Wawrowsky, Serguei Bannykh,Ines Donangelo & Shlomo Melmed

817–831

Metformin attenuates the stimulatory effectof a high-energy diet on in vivo LLC1carcinoma growth

Carolyn Algire, Mahvash Zakikhani,Marie-Jose Blouin, Jian Hua Shuai& Michael Pollak

833–839

Announcements

Author Guidelines

Number 4 $ December 2007

Androgen receptor and growth factorsignaling cross-talk in prostate cancer cells

Meng-Lei Zhu & Natasha Kyprianou 841–849

Implications of the binding of tamoxifen tothe coactivator recognition site of theestrogen receptor

Douglas J Kojetin, Thomas P Burris,Elwood V Jensen & Sohaib A Khan

851–870

The genetic basis of hereditary medullarythyroid cancer: clinical implications for thesurgeon, with a particular emphasis on therole of prophylactic thyroidectomy

George H Sakorafas, Helmut Friess& George Peros

871–884


The diagnosis and management ofparasellar tumours of the pituitary

Gregory A Kaltsas, Jane Evanson,Alexandra Chrisoulidou &Ashley B Grossman

885–903

Medical therapy for clinically non-functioning pituitary adenomas

Annamaria Colao, Carolina DiSomma, Rosario Pivonello,Antongiulio Faggiano, GaetanoLombardi & Silvia Savastano

905–915

Forkhead box-O transcription factor:critical conductors of cancer’s fate

Carl Weidinger, Kerstin Krause,Antje Klagge, Stefan Karger &Dagmar Fuhrer

917–929

Reapprasial of the role of endocrine therapyin meningioma management

Cyrus Chargari, Lionel Vedrine,Oliver Bauduceau, Sylvestre Le Moulec,Bernard Ceccaldi & Nicolas Magne

931–941

Bone mineral density in Japanese prostatecancer patients under androgen-deprivationtherapy

Wei Wang, Takeshi Yuasa, NorihikoTsuchiya, Shinya Maita, TeruakiKumazawa, Takamitsu Inoue, MitsuruSaito, Zhiyong Ma, Takashi Obara,Hiroshi Tsuruta, Shigeru Satoh &Tomonori Habuchi

943–952

Calcitonin promotes in vivo metastasis ofprostate cancer cells by altering cellsignaling, adhesion, and inflammatorypathways

Girish V Shah, Shibu Thomas,Anbalagan Muralidharan, Yong Liu,Paul L Hermonat, Jill Williams &Jaideep Chaudhary

953–964

The anandamide analog, Met-F-AEA,controls human breast cancer cell migrationvia the RHOA/RHO kinase signalingpathway

Chiara Laezza, Simona Pisanti,Anna Maria Malfitano &Maurizio Bifulco

965–974

Vitamin D receptor polymorphisms (FokI,BsmI) and breast cancer risk: associationreplication in two case–control studieswithin French Canadian population

Marc Sinotte, Francois Rousseau,Pierre Ayotte, Eric Dewailly,Caroline Diorio, Yves Giguere,Sylvie Berube & Jacques Brisson

975–983

ERBB2 influences the subcellularlocalization of the estrogen receptor intamoxifen-resistant MCF-7 cells leading tothe activation of AKT and RPS6KA2

Sunil Pancholi, Anne E Lykkesfeldt,Caroline Hilmi, Susana Banerjee,Alexandra Leary, Suzanne Drury,Stephen Johnston, Mitch Dowsett &Lesley-Ann Martin

985–1002

Signaling pathways involved in theantiproliferative effect of molecular iodinein normal and tumoral breast cells:evidence that 6-iodolactone mediatesapoptotic effects

O Arroyo-Helguera, E Rojas,G Delgado & C Aceves

1003–1011


Adenomatous polyposis coli alteration indigestive endocrine tumours: correlationwith nuclear translocation of b-catenin andchromosomal instability

Silvia Pizzi, Cinzia Azzoni, ElisaTamburini, Lorena Bottarelli,Nicoletta Campanini, Tiziana D’Adda,Giovanni Fellegara, Tu Vinh Luong,Claudio Pasquali, Giulio Rossi,Gianfranco Delle Fave, Roberta Camisa,Cesare Bordi & Guido Rindi

1013–1024

Ectopic expression of serotonin7 receptorsin an adrenocortical carcinoma co-secretingrenin and cortisol

E Louiset, K Isvi, J M Gasc,C Duparc, B Cauliez, A Laquerriere,J M Kuhn & H Lefebvre

1025–1034

I Age-related neoplastic risk profiles andpenetrance estimations in multipleendocrine neoplasia type 2A caused bygerm line RET Cys634Trp (TGCOTGG)mutation

Ioana N Milos, Karin Frank-Raue,Nelson Wohllk, Ana Luiza Maia,Eduardo Pusiol, Attila Patocs,Mercedes Robledo, Josefina Biarnes,Marta Barontini, Thera P Links,Jan Willem de Groot, Sarka Dvorakova,Mariola Peczkowska, Lisa A Rybicki,Maren Sullivan, Friedhelm Raue,Ioana Zosin, Charis Eng &Hartmut P H Neumann

1035–1041

Prospective evaluation of mitotane toxicityin adrenocortical cancer patients treatedadjuvantly

Fulvia Daffara, Silvia De Francia,Giuseppe Reimondo, Barbara Zaggia,Emiliano Aroasio, Francesco Porpiglia,Marco Volante, Angela Termine,Francesco Di Carlo, Luigi Dogliotti,Alberto Angeli, Alfredo Berruti &Massimo Terzolo

1043–1053

Association of two common single-nucleotide polymorphisms in the CYP19A1locus and ovarian cancer risk

Marc T Goodman, Galina Lurie,Pamela J Thompson, KatharineE McDuffie & Michael E Carney

1055–1060

Epithelial ovarian cancer: testing the‘androgens hypothesis’

CatherineMOlsen,AdeleCGreen,ChristinaM Nagle, Susan J Jordan, David CWhiteman,Christopher JBain&PenelopeMWebb on behalf of the Australian CancerStudy Group (Ovarian Cancer) and theAustralian Ovarian Cancer Study Group

1061–1068

Increased density of tumor-associatedmacrophages is associated with decreasedsurvival in advanced thyroid cancer

Mabel Ryder, Ronald A Ghossein,Julio C M Ricarte-Filho,Jeffrey A Knauf & James A Fagin

1069–1074

Familial non-medullary thyroid carcinomadisplays the features of clinical anticipationsuggestive of a distinct biological entity

M Capezzone, S Marchisotta,S Cantara, G Busonero, L Brilli,K Pazaitou-Panayiotou, A F Carli,G Caruso, P Toti, S Capitani,A Pammolli & F Pacini

1075–1081


Prognostic factors of long-term outcome ingastroenteropancreatic neuroendocrinetumours

Ulrich-Frank Pape, Uta Berndt,Jacqueline Muller-Nordhorn,Michael Bohmig, Stephanie Roll,Martin Koch, Stefan N Willich &Bertram Wiedenmann

1083–1097

Protein western array analysis in humanpituitary tumours: insights and limitations

Antonio Ribeiro-Oliveira Jr,Giulia Franchi, Blerina Kola,Paolo Dalino, Sergio Veloso BrantPinheiro, Nabila Salahuddin,Madalina Musat, Miklos I Goth,Sandor Czirjak, Zoltan Hanzely,Deivid Augusto da Silva,Eduardo Paulino Jr,Ashley B Grossman & Marta Korbonits

1099–1114

Clinical, genetic, and histopathologicinvestigation of CDC73-related familialhyperparathyroidism

Giulia Masi, Luisa Barzon,Maurizio Iacobone, Giovanni Viel,Andrea Porzionato, Veronica Macchi,Raffaele De Caro, Gennaro Favia &Giorgio Palu

1115–1126

Metastases but not cardiovascular mortalityreduces life expectancy following surgicalresection of apparently benignpheochromocytoma

H J L M Timmers, F M Brouwers,A R M M Hermus, F C G J Sweep,A A J Verhofstad, A L M Verbeek,K Pacak & J W M Lenders

1127–1133

Announcements

Author Guidelines

Volume Contents


Print ERC_15_4_cover

Health & Medicine

uk email

northumberland web

com web

enets email

mineral society web

aaes email

secretariat email

uk tel